DSSG Group: Genitourinary

For patients being treated for prostate cancer that has spread and who have had a good response to a standard of care hormonal combination treatment

The purpose of the De-Escalate trial is to determine whether intermittent hormonal combintation treamtment provides a favorable risk/benefit balance compared with continuous maximum androgen blockade (cMAB) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) who achieve a deep PSA response (≤ 0.2 ng/mL) after 6–12 months of treatment with ADT plus an approved androgen receptor pathway inhibitor (ARpI)

Intermediate risk non-muscle invasive bladder cancer (NMIBC)

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator’s choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.

Locally advanced unresectable or metastatic urothelial carcinoma (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra.

This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with Urothelial Cancer. This study will also test what side effects happen when participants take these drugs together.

Metastatic castration-resistant prostate cancer (mCRPC)

The purpose of this study is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC

Pathologically (histologically or cytologically) proven diagnosis of renal cell carcinoma

To determine whether the addition of stereotactic ablative radiotherapy (SABR) to the primary tumor in combination with immunotherapy improves outcomes compared to immunotherapy alone in patients with metastatic, unresected, renal cell carcinoma(RCC)

Metastatic Castration-Resistant Prostate Cancer, Prostatic Neoplasms

The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA).

Metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy.

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC with respect to overall survival (OS) and to radiographic progression-free survival (rPFS)

Castration-naïve de novo metastatic prostate cancer patients with vulnerable functional ability who have not elected for docetaxel or other androgen receptor pathway inhibitors

The purpose of the trial is to evaluate the efficacy and safety of ADT +/- darolutamide in castration-naïve de novo metastatic prostate cancer patients with vulnerable functional ability.

Testicular cancer treated with either surgery, chemotherapy or radiotherapy and completed 5 years of surveillance.

To determine incidence of late complications in testicular cancer survivors of Ireland.

Prostate Cancer being Treated with Stereotactic Body Radiotherapy

To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.